Laninamivir (R-125489) prodrug with improved in vivo efficacy than R-125489 and Zanamivir in a mouse influenza virus A (IAV) infection model.
Laninamivir octanoate (CS-8958) is the prodrug form of Laninamivir (R-125489), a potent inhibitor agianst the neuraminidase (NA) activities of various type A and B influenza viruses, including subtypes N1 to N9 and Oseltamivir-resistant strains. When administered intranasally (3X 0.2 μmol/kg; 4 h before, 4 h & 18 h post infection), CS-8958 shows improved in vivo efficacy (100% survival rate on day 20 post infecfion) than R-125489 (100/30/20% survival rate on day 7/10/20 post infecfion) and Zanamivir (100%/0% death on day 7/10) in a mouse influenza virus A/Puerto Rico/8/34 infection model, with prolonged survival effect post a single dosage given even 7 days before infection. Note: Laninamivir octanoate is mainly used for in vivo studies, it exhibits only weak to little antiviral potency before it is converted to the active drug form.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.